Is Halozyme Therapeutics (HALO) a Smart Long-Term Buy?
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Halozyme Therapeutics Inc. (HALO)
Get Email AlertsHedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 941,514 | $37,548 | -1% | 0.02% |
| 2. | Driehaus Capital Richard Driehaus | 844,063 | $33,661 | +45% | 0.41% |
| 3. | 17,444,000 | $30,242 | 0.02% | ||
| 4. | 20,000,000 | $17,609 | 0.13% | ||
| 5. | 19,500,000 | $17,152 | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | Director | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | Director | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | Director | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | Officer | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | Officer | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.42 | 12,225 | Officer, Director | 537,160 | 2021-11-08 | Filing | |
| $39.62 | 37,775 | Officer, Director | 549,385 | 2021-11-08 | Filing | |
| $40.77 | 12,548 | Director | 181,983 | 2021-11-05 | Filing | |
| $40.13 | 19,452 | Director | 194,531 | 2021-11-05 | Filing | |
| $40.95 | 5,857 | Officer, Director | 537,160 | 2021-10-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 3,867,000 | $6,742,331 | 0% | |
| 2. | 167,465 | $6,678,504 | 0% | |
| 3. | 75,000 | $2,991,000 | 0.06% | |
| 4. | 45,391 | $1,810,193 | 0% | |
| 5. | 19,670,225 | $784,449 | 0.02% |
News See All
Is Halozyme Therapeutics (HALO) A Worthy Long-Term Investment?
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
15 Best Stocks to Buy for 2022 According to Analysts
In this article, we discuss the 15 best stocks to buy for 2022 according to analysts.
Halozyme Therapeutics, Inc. (HALO) Fell Out Of Favor With Hedge Funds
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Are Cashing Out Of Halozyme Therapeutics, Inc. (HALO)
In this article you are going to find out whether hedge funds think Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a good investment right now.
Is HALO Stock A Buy or Sell?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Is Halozyme Therapeutics (HALO) A Smart Long-Term Buy?
Artisan Partners Limited Partnership, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2020 investor letter – a copy of which can be downloaded...
Hedge Funds Are Getting Bullish On Halozyme Therapeutics, Inc. (HALO)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Did Hedge Funds Make The Right Call On Halozyme Therapeutics, Inc. (HALO) ?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
